Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Belgium

- PMLiVE

Pfizer calls for mHealth to be prioritised

Wants more action to support mobile health in developing countries' ageing populations

- PMLiVE

Xeljanz effective in psoriasis says Pfizer

Data backs extension of drug’s indications

ABPI London offices

ABPI announces review of Code

Trade body to update standards for pharma industry in UK

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

Adobe CEO joins Pfizer board

Shantanu Narayen joins corporate governance and science and technology committees

- PMLiVE

Pfizer’s Xalkori ‘not good value for money’, says NICE

Final guidance does not recommend lung cancer drug

- PMLiVE

Eisai lines-up Fycompa access programme for Germany

But sales suspension for epilepsy drug will continue

- PMLiVE

Gedeon Richter falls foul of ABPI

Hungarian pharma company found to have breached Code of Practice

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

- PMLiVE

ABPI appoints new head of media

Lisa Potter to join from NHS Direct

- PMLiVE

The evolution of IQWiG in Germany’s drug pricing policy

Over the past ten years Germany has created a well-oiled machine designed to ensure that it gets the best deal when it comes to drug prices

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links